Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis

Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis

The use of rituximab (RTX), an anti-CD20 monoclonal antibody (Ab), in refractory myasthenia gravis (MG) is associated with a better response in patients with Abs to the muscle-specific tyrosine kinase (MuSK) than in other MG subgroups. Anti-MuSK Abs are mostly IgG4 with proven pathogenicity and posi...

Full description

Bibliographic Details
Main Authors: Mariapaola Marino, Umberto Basile, Gregorio Spagni, Cecilia Napodano, Raffaele Iorio, Francesca Gulli, Laura Todi, Carlo Provenzano, Emanuela Bartoccioni, Amelia Evoli
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Immunology
Subjects:
rituximab
antibodies
MuSK
myasthenia gravis
IgG4
short-lived antibody-secreting cells
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.00613/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.00613/full

Similar Items